Examination of the response of breast cancer cells, altered in p53 status, to doxorubicin

被引：0
|
作者：
Paulin, FEM [1 ]
Wardrop, J [1 ]
Ward, C [1 ]
Lane, DP [1 ]
Rankin, EM [1 ]
Thompson, AM [1 ]
Wolf, CR [1 ]
机构：
[1] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] Role of p53 in determining response of breast cancer cells to chemotherapy
    Hinnis, A
    Luckett, J
    Walker, RA
    JOURNAL OF PATHOLOGY, 2003, 201 : 27A - 27A
  • [2] Angiogenesis in breast cancer: Association with P53 status
    不详
    EUROPEAN CYTOKINE NETWORK, 2004, 15 (04) : IV - IV
  • [3] YRole of cystamine in autophagy of breast cancer cells with different status of p53
    Parfenyev, Sergey
    Daks, Alexandra
    Fedorova, Olga
    Barlev, Nickolai
    CELL DEATH DISCOVERY, 2021, 7 (SUPPL 1) : 9 - 9
  • [4] p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines
    Fernandez-Cuesta, Lynnette
    Anaganti, Suresh
    Hainaut, Pierre
    Olivier, Magali
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (08) : 1813 - 1821
  • [5] Radiosensitivity of human breast cancer cells transduced with wild-type p53 gene is influenced by the p53 status of parental cells
    Maeda, T
    Matsubara, H
    Koide, Y
    Sugaya, M
    Miyazawa, Y
    Tasaki, K
    Isono, K
    Ochiai, T
    Sakiyama, S
    Tagawa, M
    ANTICANCER RESEARCH, 2000, 20 (2A) : 869 - 874
  • [6] Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
    Johanna Huun
    Per Eystein Lønning
    Stian Knappskog
    Cell Death Discovery, 3
  • [7] Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
    Huun, Johanna
    Lonning, Per Eystein
    Knappskog, Stian
    CELL DEATH DISCOVERY, 2017, 3
  • [8] Molecular basis for the accelerated senescence response to doxorubicin in p53 wild-type and p53 null/mutant breast tumor cells.
    Di, Xu
    Gewirtz, David
    CANCER RESEARCH, 2009, 69
  • [9] Clinicopathological analysis of the p53 expression status in breast cancer
    Kikuyama, M.
    Kunimata, H.
    Oka, T.
    Tachibana, A.
    BREAST, 2015, 24 : S111 - S112
  • [10] Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer
    Anelli, A
    Brentani, RR
    Gadelha, AP
    de Albuquerque, AA
    Soares, F
    ANNALS OF ONCOLOGY, 2003, 14 (03) : 428 - 432
12345